| Patent application number | Description | Published |
|---|
| 20080207730 | Methods of using (+)-2-[1-(3-Ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione - Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 08-28-2008 |
| 20080234359 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof - Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 09-25-2008 |
| 20080242719 | Methods of Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline- 1,3-Dione - Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 10-02-2008 |
| 20100160405 | METHODS OF USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE 1,3-DIONE - Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 06-24-2010 |
| 20100168475 | PROCESSES FOR THE PREPARATION OF AMINOSULFONE COMPOUNDS - Processes for synthesizing aminosulfone compounds are provided. Aminosulfone compounds obtained using methods provided herein are useful in production or synthesis of isoindoline based PDE 4 modulators. | 07-01-2010 |
| 20110087033 | Processes for the Preparation of 2-(1-Phenylethyl)isoindolin-1-one Compounds - Methods for preparation of isoindolin-1-one compounds are described. | 04-14-2011 |
| 20110112307 | SOLID FORMS COMPRISING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOI- SOINDOLINE-1,3-DIONE, COMPOSITIONS THEREOF, AND USES THEREOF - Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4. | 05-12-2011 |
| 20110224440 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS - The present invention provides new processes for the preparation of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds which are useful, for example, for preventing or treating diseases or conditions related to an abnormally high level or activity of TNF-α. The invention can provide improved and/or efficient processes for the commercial production of unsubstituted and substituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds, including, but not limited to, unsubstituted 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. | 09-15-2011 |
| Patent application number | Description | Published |
|---|
| 20090253673 | Substituted Pyrazoles as Ghrelin Receptor Antagonists - Certain novel N-acylated spiropiperidine derivatives are ligands of the human ghrelin receptor(s) and, in particular, are antagonists/inverse agonists of the human ghrelin receptor. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of the ghrelin receptor, such as obesity, diabetes, and metabolic syndrome. | 10-08-2009 |
| 20090312303 | Antidiabetic Bicyclic Compounds - Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 12-17-2009 |
| 20100105725 | ANTIDIABETIC BICYCLIC COMPOUNDS - Diaryl ethers in which one of the aryl groups is a phenyl fused to a cycloalkyl or heterocyclic ring, to which is attached an acetic acid group, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes mellitus, and of conditions that often accompany this disease, including insulin resistance, obesity and lipid disorders. | 04-29-2010 |
| Patent application number | Description | Published |
|---|
| 20090262650 | METHOD AND APPARATUS FOR PROVIDING STATISTICAL EVENT CORRELATION IN A NETWORK - A method and apparatus for providing event correlation in a network are disclosed. For example, the method extracts a plurality of events of interest from a database, and creates one or more event time series from the plurality of events of interest, wherein each of the one or more event time series comprises a set of events of a same type and of a same location that occur within a given time period. The method forms one or more composite events from the one or more event time series, and performs one or more pair-wise correlations for at least one of: the event time-series, or the one or more composite events. The method then identifies one or more pair-wise correlations that are statistically significant. | 10-22-2009 |
| 20100014420 | Lightweight Application Classification for Network Management - Managing network traffic to improve availability of network services by classifying network traffic flows using flow-level statistical information and machine learning estimation, based on a measurement of at least one of relevance and goodness of network features. Also, determining a network traffic profile representing applications associated with the classified network traffic flows, and managing network traffic using the network traffic profile. The flow-level statistical information includes packet-trace information and is available from at least one of Cisco NetFlow, NetStream or cflowd records. The classification of network flows includes tagging packet-trace flow record data based on defined packet content information. The classifying of network flows can result in the identification of a plurality of clusters based on the measurement of the relevance of the network features. Also, the classification of network traffic can use a correlation-based measure to determine the goodness of the network features. | 01-21-2010 |
| 20100034102 | Measurement-Based Validation of a Simple Model for Panoramic Profiling of Subnet-Level Network Data Traffic - A system and method for profiling subnet-level aggregate network data traffic is disclosed. The system allows a user to define a collection of features that combined characterize the subnet-level aggregate traffic behavior. Preferably, the features include daily traffic volume, time-of-day behavior, spatial traffic distribution, traffic balance in flow direction, and traffic distribution in type of application. The system then applies machine learning techniques to classify the subnets into a number of clusters on each of the features, by assigning a membership probability vector to each network thus allowing panoramic traffic profiles to be created for each network on all features combined. These membership probability vectors may optionally be used to detect network anomalies, or to predict future network traffic. | 02-11-2010 |
| 20110307913 | Modeling User Activity Information Associated with a Network System - Systems and methods to model user activity information associated with a network system are provided. A particular method includes receiving, at a computing device, a request for user activity information associated with selected channels of a television access network that provides multimedia content to users. The method includes executing a model of user activity associated with the television access network at the computing device. The model estimates the user activity information as user multimedia access demands during particular time periods within a day. The method also includes storing the user activity information at a computer-readable non-transitory storage medium. | 12-15-2011 |
